# Junta clínica — PT-pseudo_f99f0627e536 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f99f0627e536",
  "pid": "PT-pseudo_f99f0627e536",
  "task": 1,
  "psa": 10.0,
  "age": 70,
  "months": 2,
  "pirads": "5",
  "psad": 0.349,
  "psav": 2.0,
  "psap": 5.6,
  "vol": 28.64,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.83261764,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 29 mL. csPCa 0.83.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "112 kg",
    "height": "181 cm",
    "bmi": "34.2",
    "bp": "104/81 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Post-prostatectomy monitoring revealed a PSA increase to 10.0 ng/mL, necessitating immediate specialist review."
    },
    {
      "s": "History",
      "t": "At age seventy, the patient works as a retired greenhouse horticulturalist and resides with his wife. After an initial PSA elevation in 2022 prompted a radical prostatectomy when he was sixty-nine, he has maintained strict surveillance protocols. His current PSA stands at 10.0 ng/mL. He reports no urinary blockage, blood in the urine, or skeletal discomfort, recording a minimal IPSS of 1 out of 35. Alcohol consumption averages twenty-six units per week, and he regularly hikes on weekends. Beyond urological matters, he completed a six-session physiotherapy regimen for persistent lower back strain and underwent baseline cognitive screening at a memory clinic; both interventions are progressing without complication. He smokes nothing and requires no daily pharmacotherapy."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth; mobility: unrestricted; asymmetry: absent. The prostatic fossa presents symmetrically without palpable irregularities. Vital signs remain stable, and systemic examination shows no acute abnormalities. While a walking frame assists him during extended ambulation, his baseline functional capacity remains solid for routine tasks."
    }
  ],
  "occupation": "retired greenhouse horticulturalist",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Memory clinic — baseline screening",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "26 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f99f0627e536
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.349 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 28.64 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83261764 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 29 mL. csPCa 0.83.

Vitals: weight 112 kg, height 181 cm, BMI 34.2, BP 104/81 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Post-prostatectomy monitoring revealed a PSA increase to 10.0 ng/mL, necessitating immediate specialist review.

History: At age seventy, the patient works as a retired greenhouse horticulturalist and resides with his wife. After an initial PSA elevation in 2022 prompted a radical prostatectomy when he was sixty-nine, he has maintained strict surveillance protocols. His current PSA stands at 10.0 ng/mL. He reports no urinary blockage, blood in the urine, or skeletal discomfort, recording a minimal IPSS of 1 out of 35. Alcohol consumption averages twenty-six units per week, and he regularly hikes on weekends. Beyond urological matters, he completed a six-session physiotherapy regimen for persistent lower back strain and underwent baseline cognitive screening at a memory clinic; both interventions are progressing without complication. He smokes nothing and requires no daily pharmacotherapy.

Physical examination: DRE — texture: smooth; mobility: unrestricted; asymmetry: absent. The prostatic fossa presents symmetrically without palpable irregularities. Vital signs remain stable, and systemic examination shows no acute abnormalities. While a walking frame assists him during extended ambulation, his baseline functional capacity remains solid for routine tasks.

Patient info: retired greenhouse horticulturalist; Married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Memory clinic — baseline screening; Physiotherapy — lower back, six sessions.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.09 epistemic (95% band 0.46-0.80); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.66: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"
  2. distance 0.72: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"
  3. distance 0.74: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."

PRECEDENT: BIOPSY (weighted vote 0.64 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the need for repeat biopsy after a prior positive biopsy, focusing on histological progression and imaging findings. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This requires assessing the current MRI findings against the prior biopsy result to determine if histological progression is indicated.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I find the bid for biopsy is not settled because the guideline makes decisive that the documented grade of the prior biopsy and the surveillance history are key, which the panel variables alone do not capture. EXPERT-COHORT, the criterion confirms that the visible panel does not determine this decision because the documented grade of the prior biopsy and the surveillance history live in the previous notes.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA has normalized: if the PSA has normalised, a new PSA test can be performed after one year
laboratory_results - whether the PSA has normalized: the type of PSA assay used may impact PSA values and rates of PSA above certain fixed thresholds

THE FOLLOWING VALUES ARE ALREADY KNOWN and a line about any of them is wrong:
age - 70
PSA - 10.0 ng/mL
PI-RADS - 5
PSA density - 0.349 ng/mL²
prostate volume - 28.64 mL
DRE finding - Normal
prior-biopsy status - Positive
csPCa probability - 0.83261764

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade of the prior biopsy and the surveillance history detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the lesion in the MRI is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine if the PSA has normalized.
  previous_notes (get_previous_notes) -> Determine the grade of the prior biopsy and surveillance status.
  laboratory_results (get_lab_results) -> Determine if the PSA has normalized.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. previous_notes: What is the grade (Gleason/ISUP) of the prior biopsy?
  Q2. previous_notes: Is the patient currently on a surveillance protocol with a confirmatory biopsy due?
  Q3. radiology_report: Is the lesion in the MRI compared against an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 5 lesion in the left mid-gland prostatic remnant, size 12 x 9 x 11 mm.
psa_trend
The PSA trend shows a rise from 2.0 (Jan 2022) to 4.5 (Jul 2023) to 10.0 (Jan 2025).
previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: not recorded
TREATMENT: none recorded
laboratory_results
The PSA has not normalized, with the latest measurement being "10.0 ng/mL" on "25 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already addressed the relevant surveillance history.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left mid-gland prostatic remnant, as per the radiology report.
PSA trend shows a clear upward trajectory, indicating progression.
AGAINST sampling this patient now
The previous notes do not document the grade of the prior biopsy, which is a key factor.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 10.00 ng/mL over 3 points spanning 36 months; velocity +2.67 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 16.6 ng/mL, conformal 95% band 4.8-57.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.08 epistemic (95% band 0.42-0.75), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.59  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.64  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.60 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered all three moderator questions. The `previous_notes` provided information regarding the prior biopsy status and surveillance, the `radiology_report` addressed the comparison status, and the `psa_trend` and `laboratory_results` addressed PSA normalization.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a weighted vote for BIOPSY based on the experts' consensus, despite the lack of a documented prior grade in the opened documents. The retrieved findings, particularly the rising PSA trend and the PI-RADS 5 lesion in the MRI, align with the expert consensus leaning towards biopsy.

THE OPEN QUESTIONS, ONE BY ONE
Q1. previous_notes: What is the grade (Gleason/ISUP) of the prior biopsy? Answered by the registrar: "PRIOR GRADE: not recorded".
Q2. previous_notes: Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the registrar: "SURVEILLANCE: not recorded".
Q3. radiology_report: Is the lesion in the MRI compared against an earlier study? Answered by the registrar: "COMPARISON: new".

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables for the EAU guideline are the documented grade of the prior biopsy and the surveillance history, as these determine the indication for repeat biopsy. The lack of documentation for these specific points is a critical gap.

MY SUGGESTION TO THE CHAIR
Given that the key factors determining the decision—the prior biopsy grade and surveillance status—are explicitly not recorded in the retrieved documents, the guideline suggests a need for further information before a definitive decision can be made.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

70y male, PSA 10.0, PI-RADS 5, prior positive biopsy with unrecorded grade. New PI-RADS 5 lesion mandates repeat biopsy to confirm histological progression. Prior grade is not recorded, making sampling necessary to determine management pathway.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
